To study the ability of allogeneic activated NK cells to eliminate different types of CRC, we established a CRC cell line collection with different mutational statuses on the EGFR pathway (Ras/Raf; PI3K/AKT) and p53 (Supplementary Table 3). This evidence concerns the gene TP53 and colorectal carcinoma.